Sign inJoin waitlistJoin the waitlist

Peter Cole

Chief, Division of Pediatric Hematology/Oncology · Rutgers Health

Credentials: · ·

History

Division of Pediatric Hematology/Oncology · Rutgers Health
Present
New Jersey Pediatric Hematology and Oncology Research Center of Excellence · Rutgers Health
Present
Rutgers Health
Present

Memorial Sloan Kettering Cancer Center
1996–1997
Mount Sinai Medical Center
1993–1996
Weill Cornell Medicine
1989–1993

Research

Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000)
Leukemia · 2010 · 240 citations
Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a…
The Lancet Oncology · 2015 · 208 citations
Dextromethorphan is effective in the treatment of subacute methotrexate neurotoxicity
Pediatric Hematology and Oncology · 2002 · 105 citations

Kara Kelly
50 papers
Lewis Silverman
38 papers
Jennifer Welch
27 papers
Stephen Sallan
23 papers
Justine Kahn
21 papers · 2 as a fellow
LC
Luis Clavell
19 papers
BK
Barton Kamen
18 papers
MS
Marshall Schorin
18 papers
Lisa Gennarini
17 papers
Richard Drachtman
15 papers
Barbara Asselin
13 papers
Lynda Vrooman
10 papers

Grants

Metformin to Prevent Chemotherapy-Induced Neurotoxicity Among Children with Leukemia
National Cancer Institute · R01
Contact PI · $600.9K · Rutgers Biomedical and Health Sciences
2026–2031
Identification of Novel Biomarkers and Therapeutic Strategies in Chemobrain.
National Cancer Institute · R01
PI · $3M · Rutgers Biomedical and Health Sciences
2024–2029
Characterization of Brain Dysfunction During Development in Survivors of Childhood Acute Lymphoblastic Leukemia
National Cancer Institute · R01
PI · $4.6M · Albert Einstein College of Medicine
2020–2026
Identifying Children with Subclinical Neurocognitive Decline and Susceptibility to Oxidative Damage During the Early Months of Therapy for ALL
National Cancer Institute · R01
Contact PI · $3.4M · Rutgers Biomedical and Health Sciences
2018–2024

Clinical trials

Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma
Principal investigator · Completed · Phase 1, Phase 2
National Cancer Institute (NCI)
2013–2021
Gemcitabine and Vinorelbine in Treating Young Patients With Recurrent or Refractory Hodgkin's Lymphoma
Study chair · Completed · Phase 2
Children's Oncology Group
2004